Trials / Completed
CompletedNCT01318304
Vaginal Innate Immunity in Normal and HIV-Infected Women
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 83 (actual)
- Sponsor
- Boston Medical Center · Academic / Other
- Sex
- Female
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Accepted
Summary
The innate immunity of the vaginal tract provides first-line defense from abnormal microorganisms or overgrowth of common organisms, such as Candida species or Gardnerella vaginalis. It is unclear from the current available literature whether the rate of vaginal infection increases or decreases in frequency during pregnancy when compared to the non-pregnant state, but this may be predicted by shifts in vaginal innate immunity. Vaginal infections are important players in HIV disease, potentially increasing the risk of viral transmission. In addition, these infections may activate inflammatory markers in the reproductive tract and increase the risk of premature delivery or other negative pregnancy outcomes. The vaginal innate immune system has not been well characterized in pregnant women, or in women with HIV infection. The study of how this system changes in pregnancy and HIV infection will provide essential knowledge for further study of vaginal mucosal protection. The investigators study is an observational study designed to compare levels of vaginal innate immunity markers in women based on a) pregnancy status and b) HIV infection status. Comparisons will be made between pregnant and non- pregnant women and between HIV positive and HIV negative women. The investigators hypothesize that there will be significant differences in levels of innate immunity between the groups.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Vaginal lavage specimen | Collection of 3cc of saline used in the vagina to collect innate immunity markers |
Timeline
- Start date
- 2010-10-01
- Primary completion
- 2013-04-01
- Completion
- 2013-04-01
- First posted
- 2011-03-18
- Last updated
- 2016-05-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01318304. Inclusion in this directory is not an endorsement.